Minimal Residual Disease Mrd Liquid Biopsy Market
Minimal Residual Disease (MRD) Liquid Biopsy Market Forecasts to 2034 - Global Analysis By Product (NGS-Based MRD Assays, PCR-Based MRD Assays, Digital PCR MRD Tests, Cell-Free DNA MRD Tests, Other Products), By Cancer Type, By Sample Type, By Technology, By End User and By Geography
According to Stratistics MRC, the Global Minimal Residual Disease (MRD) Liquid Biopsy Market is accounted for $1.9 billion in 2026 and is expected to reach $4.7 billion by 2034 growing at a CAGR of 12% during the forecast period. Minimal Residual Disease (MRD) Liquid Biopsy refers to highly sensitive diagnostic tests that detect small numbers of remaining cancer cells in a patient’s body after treatment. These tests analyze circulating tumor DNA (ctDNA), circulating tumor cells, or other biomarkers in blood samples to identify early signs of relapse. MRD detection allows clinicians to monitor treatment effectiveness, adjust therapies, and detect recurrence earlier than conventional imaging methods. As a non-invasive diagnostic tool, MRD liquid biopsy supports personalized oncology care, enabling more precise disease monitoring and improved long-term cancer management.
Market Dynamics:
Driver:
Increasing cancer prevalence worldwide
As cancer incidence continues to rise, there is a growing need for advanced diagnostic tools that can detect disease recurrence at very early stages. MRD liquid biopsy technologies enable the detection of small amounts of cancer cells remaining in the body after treatment. These tests provide a non-invasive and highly sensitive method for monitoring treatment response and disease progression. Healthcare providers are increasingly adopting MRD testing to improve patient outcomes through early intervention. As oncology diagnostics evolve, the demand for MRD liquid biopsy solutions is expected to grow significantly.
Restraint:
Limited clinical validation in some cancers
Although MRD testing has demonstrated strong clinical utility in hematological malignancies such as leukemia, its effectiveness in some solid tumors is still under investigation. The lack of standardized testing protocols and validation studies across multiple cancer types can limit broader clinical adoption. Healthcare providers often require strong clinical evidence before incorporating new diagnostic technologies into routine practice. Additionally, regulatory approvals can be delayed when sufficient clinical data is unavailable. These challenges may slow the widespread implementation of MRD liquid biopsy technologies.
Opportunity:
Integration with precision medicine approaches
Precision medicine focuses on tailoring treatments based on a patient’s genetic and molecular profile. MRD testing provides valuable molecular insights that help clinicians determine treatment effectiveness and identify potential relapse. This information can guide personalized treatment decisions and targeted therapy selection. Pharmaceutical companies are also incorporating MRD biomarkers into clinical trials to evaluate the effectiveness of new cancer therapies. As personalized oncology continues to expand, the role of MRD liquid biopsy technologies in precision medicine is expected to increase substantially.
Threat:
Competition from traditional biopsy methods
Conventional tissue biopsies remain widely used for cancer diagnosis and monitoring. Many healthcare providers still rely on established biopsy techniques due to their long history of clinical validation. In some cases, tissue biopsies provide more detailed information about tumor structure and characteristics. Additionally, the cost and availability of MRD liquid biopsy tests may limit their adoption in certain healthcare settings. These factors create competitive pressure on the adoption of liquid biopsy technologies in oncology diagnostics.
Covid-19 Impact:
The COVID-19 pandemic had a notable impact on the Minimal Residual Disease Liquid Biopsy market. During the early stages of the pandemic, many cancer screening and diagnostic procedures were delayed due to healthcare system disruptions. Clinical trials related to oncology diagnostics also experienced temporary slowdowns. However, the pandemic increased interest in non-invasive diagnostic technologies that reduce hospital visits and patient exposure to infections. MRD liquid biopsy tests, which require simple blood samples, gained attention as a safer and more convenient monitoring tool. As healthcare systems recovered, investments in advanced cancer diagnostics resumed.
The leukemia segment is expected to be the largest during the forecast period
The leukemia segment is expected to account for the largest market share during the forecast period as MRD testing has shown strong clinical effectiveness in hematological cancers. Leukemia patients often require continuous monitoring after treatment to detect possible disease relapse. MRD liquid biopsy techniques allow clinicians to identify minimal cancer cells that remain in the bloodstream after therapy. Early detection of residual disease enables timely treatment adjustments and improved patient outcomes. Healthcare providers increasingly rely on MRD testing for risk stratification and treatment planning in leukemia cases.
The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate due to increasing use of MRD biomarkers in drug development and clinical trials. Pharmaceutical firms are utilizing MRD testing to evaluate the effectiveness of novel cancer therapies. MRD data can help accelerate clinical trial outcomes by providing early indicators of treatment response. The growing focus on targeted therapies and immunotherapies is further increasing the importance of molecular diagnostics. Collaborations between diagnostic companies and pharmaceutical manufacturers are also expanding in this area.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share owing to strong research infrastructure and advanced healthcare systems. The region has a high adoption rate of innovative diagnostic technologies in oncology care. Leading biotechnology companies and diagnostic laboratories are actively developing MRD liquid biopsy solutions in this region. Government funding and regulatory support for cancer research also contribute to market growth. Additionally, the rising prevalence of cancer and growing awareness of precision medicine further support the adoption of MRD diagnostics.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by increasing cancer incidence and expanding healthcare infrastructure. Countries such as China, Japan, South Korea, and India are investing heavily in advanced cancer diagnostics and research programs. The growing adoption of molecular diagnostic technologies is improving cancer detection and monitoring capabilities in the region. Additionally, rising healthcare expenditure and government initiatives supporting precision medicine are encouraging market expansion. International collaborations and clinical research activities are also increasing across Asia Pacific.
Key players in the market
Some of the key players in Minimal Residual Disease (MRD) Liquid Biopsy Market include Natera, Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Adaptive Biotechnologies Corporation, IQVIA Holdings Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Invitae Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., ArcherDx, Inc., NeoGenomics Laboratories, Exact Sciences Corporation, GRAIL, LLC and BGI Genomics.
Key Developments:
In January 2026, Natera and Exelixis announced a collaboration on the STELLAR-316 trial, a randomized Phase 3 study that will use Natera’s Signatera test to identify MRD-positive patients with resected Stage II/III colorectal cancer for evaluation of the drug zanzalintinib.
In April 2025, Guardant Health announced an agreement with Bayshore HealthCare to offer its precision oncology tests through Bayshore's network of clinics in Canada . This partnership will provide Canadian patients with access to the Guardant Reveal™ blood test for MRD detection and recurrence monitoring in early-stage cancer.
Products Covered:
• NGS-Based MRD Assays
• PCR-Based MRD Assays
• Digital PCR MRD Tests
• Cell-Free DNA MRD Tests
• Other Products
Cancer Types Covered:
• Hematological Malignancies
• Leukemia
• Lymphoma
• Multiple Myeloma
• Solid Tumors
• Other Cancer Types
Sample Types Covered:
• Blood
• Bone Marrow
• Plasma
• Serum
• Other Sample Types
Technologies Covered:
• Next-Generation Sequencing (NGS)
• Real-Time PCR
• Digital Droplet PCR
• BEAMing Technology
• Flow Cytometry
• Other Technologies
End Users Covered:
• Hospitals
• Oncology Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical Companies
• Other End Users
Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
§ Saudi Arabia
§ United Arab Emirates
§ Qatar
§ Israel
§ Rest of Middle East
o Africa
§ South Africa
§ Egypt
§ Morocco
§ Rest of Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 Research Framework
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 Market Dynamics and Trend Analysis
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 Competitive and Strategic Assessment
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Product
5.1 NGS-Based MRD Assays
5.2 PCR-Based MRD Assays
5.3 Digital PCR MRD Tests
5.4 Cell-Free DNA MRD Tests
5.5 Other Products
6 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Cancer Type
6.1 Hematological Malignancies
6.2 Leukemia
6.3 Lymphoma
6.4 Multiple Myeloma
6.5 Solid Tumors
6.6 Other Cancer Types
7 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Sample Type
7.1 Blood
7.2 Bone Marrow
7.3 Plasma
7.4 Serum
7.5 Other Sample Types
8 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Technology
8.1 Next-Generation Sequencing (NGS)
8.2 Real-Time PCR
8.3 Digital Droplet PCR
8.4 BEAMing Technology
8.5 Flow Cytometry
8.6 Other Technologies
9 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By End User
9.1 Hospitals
9.2 Oncology Clinics
9.3 Diagnostic Laboratories
9.4 Academic & Research Institutes
9.5 Pharmaceutical Companies
9.6 Other End Users
10 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Geography
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 United Kingdom
10.2.2 Germany
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Netherlands
10.2.7 Belgium
10.2.8 Sweden
10.2.9 Switzerland
10.2.10 Poland
10.2.11 Rest of Europe
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Australia
10.3.6 Indonesia
10.3.7 Thailand
10.3.8 Malaysia
10.3.9 Singapore
10.3.10 Vietnam
10.3.11 Rest of Asia Pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Colombia
10.4.4 Chile
10.4.5 Peru
10.4.6 Rest of South America
10.5 Rest of the World (RoW)
10.5.1 Middle East
10.5.1.1 Saudi Arabia
10.5.1.2 United Arab Emirates
10.5.1.3 Qatar
10.5.1.4 Israel
10.5.1.5 Rest of Middle East
10.5.2 Africa
10.5.2.1 South Africa
10.5.2.2 Egypt
10.5.2.3 Morocco
10.5.2.4 Rest of Africa
11 Strategic Market Intelligence
11.1 Industry Value Network and Supply Chain Assessment
11.2 White-Space and Opportunity Mapping
11.3 Product Evolution and Market Life Cycle Analysis
11.4 Channel, Distributor, and Go-to-Market Assessment
12 Industry Developments and Strategic Initiatives
12.1 Mergers and Acquisitions
12.2 Partnerships, Alliances, and Joint Ventures
12.3 New Product Launches and Certifications
12.4 Capacity Expansion and Investments
12.5 Other Strategic Initiatives
13 Company Profiles
13.1 Natera, Inc.
13.2 F. Hoffmann-La Roche Ltd.
13.3 Guardant Health, Inc.
13.4 Adaptive Biotechnologies Corporation
13.5 IQVIA Holdings Inc.
13.6 Illumina, Inc.
13.7 Thermo Fisher Scientific Inc.
13.8 Invitae Corporation
13.9 Agilent Technologies, Inc.
13.10 Bio-Rad Laboratories, Inc.
13.11 ArcherDx, Inc.
13.12 NeoGenomics Laboratories
13.13 Exact Sciences Corporation
13.14 GRAIL, LLC
13.15 BGI Genomics
List of Tables
1 Global Minimal Residual Disease (MRD) Liquid Biopsy Market Outlook, By Region (2023-2034) ($MN)
2 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Product (2023–2034) ($MN)
3 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By NGS-Based MRD Assays (2023–2034) ($MN)
4 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By PCR-Based MRD Assays (2023–2034) ($MN)
5 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Digital PCR MRD Tests (2023–2034) ($MN)
6 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Cell-Free DNA MRD Tests (2023–2034) ($MN)
7 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Other Products (2023–2034) ($MN)
8 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Cancer Type (2023–2034) ($MN)
9 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Hematological Malignancies (2023–2034) ($MN)
10 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Leukemia (2023–2034) ($MN)
11 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Lymphoma (2023–2034) ($MN)
12 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Multiple Myeloma (2023–2034) ($MN)
13 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Solid Tumors (2023–2034) ($MN)
14 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Other Cancer Types (2023–2034) ($MN)
15 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Sample Type (2023–2034) ($MN)
16 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Blood (2023–2034) ($MN)
17 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Bone Marrow (2023–2034) ($MN)
18 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Plasma (2023–2034) ($MN)
19 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Serum (2023–2034) ($MN)
20 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Other Sample Types (2023–2034) ($MN)
21 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Technology (2023–2034) ($MN)
22 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Next-Generation Sequencing (NGS) (2023–2034) ($MN)
23 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Real-Time PCR (2023–2034) ($MN)
24 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Digital Droplet PCR (2023–2034) ($MN)
25 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By BEAMing Technology (2023–2034) ($MN)
26 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Flow Cytometry (2023–2034) ($MN)
27 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Other Technologies (2023–2034) ($MN)
28 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By End User (2023–2034) ($MN)
29 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Hospitals (2023–2034) ($MN)
30 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Oncology Clinics (2023–2034) ($MN)
31 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Diagnostic Laboratories (2023–2034) ($MN)
32 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Academic & Research Institutes (2023–2034) ($MN)
33 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Pharmaceutical Companies (2023–2034) ($MN)
34 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Other End Users (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
